Clinical trials: Metastatic Malignant Neoplasm to Brain
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
The objectives of the study is to determine if either temozolomide or erlotinib combined with WBRT and SRS improves survival as compared to WBRT and SRS alone.Ptients with histologically confirmed NSCLC with the presence of 1-3…
- Trial name
- NCT00268684
- Testing
- Erlotinib, Temozolomide
- Where
- Israel
- Volunteers
- 381 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Breast Cancer, Brain Metastases
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain.
- Trial name
- NCT00470847
- Testing
- Lapatinib, Whole Brain Radiation, Herceptin
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Nancy Lin, MD
Non-small Cell Lung Cancer
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by…
- Trial name
- NCT04345146
- Testing
- FSRT combined with Bevacizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Brain Metastases, Lung Cancer
Brigatinib Before Brain Irradiation Trial (B3i Trial)
This is a single arm phase II study of brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a…
- Trial name
- NCT04634110
- Testing
- Brigatinib
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, etoposide phosphate, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00238173
- Testing
- filgrastim, acetylcysteine, carboplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Malignant Tumors, Brain Lymphoma
Usefulness of Gadovist-enhanced FLAIR Imaging
Polyplastic glioblastoma and metastatic brain cancer are the most common malignant brain tumors in adults. The primary diagnostic test for tumors in the brain shows magnetic resonance imaging or similar imaging findings…
- Conditions
- Malignant Tumors, Brain Lymphoma, CNS Lymphoma
- Trial name
- NCT05293990
- Testing
- Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Ryoo, In Seon
HER2-positive Metastatic Breast Cancer
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
This study evaluates the efficacy and safety of SRT combined with pyrotinib and capecitabine in the treatment of patients with HER2-positive advanced breast cancer patients with brain metastases.
- Trial name
- NCT05042791
- Testing
- radiation combined with pyrotinib and capecitabine
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
SCLC, Brain Metastases
Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases
Patients suffering from small cell lung cancer (SCLC) are at high risk for developing brain metastases (BM). To prevent a clinical manifestation of preexisting microscopic brain dissemination, prophylactic cranial irradiation…
- Trial name
- ENCEPHALON (NCT03297788)
- Testing
- SRS, WBRT
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- Juergen Debus
EGFR-mutated Lung Adenocarcinoma, Brain Metastasis
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
Multicentre randomised (1:1) trial assessing the efficacy of whole brain radiotherapy in addition to Gefitinib for the management of brain metastasis in lung cancer patients with a mutated EGFR.
- Trial name
- ARPEGE (NCT01363557)
- Testing
- whole brain radiotherapy, Gefitinib (IRESSA)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cognitive/Functional Effects, Metastatic Cancer
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain…
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01227954
- Testing
- intensity-modulated radiation therapy
- Where
- 63 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Radiation Therapy Oncology Group
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Brain Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have brain…
- Trial name
- NCT00005954
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Duke University
Brain Metastases
Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases
This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)
- Trial name
- NCT06405256
- Testing
- magnetic resonance imaging-guided adaptive radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer, Metastatic Cancer
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00238251
- Testing
- gefitinib, temozolomide, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 59 people
- Sponsor
- Swiss Cancer Institute
Brain and Central Nervous System Tumors, Lung Cancer
Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer
RATIONALE: Cilengitide may stop the growth of brain metastases by blocking blood flow to the tumor. Radiation therapy uses high energy X-rays to kill tumor cells.
- Trial name
- CIRAB (NCT00884598)
- Testing
- cilengitide, pharmacological study, radiation therapy
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Universitätsmedizin Mannheim
Leptomeningeal Disease, Glioblastoma
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or…
- Conditions
- Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer
- Trial name
- GUIDE-CNS (NCT07689721)
- Testing
- CSF ctDNA-Guided Clinical Management
- Volunteers
- 77 people
- Sponsor
- Alireza Mansouri
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases
ANG1005 in Leptomeningeal Disease From Breast Cancer
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated…
- Conditions
- Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
- Trial name
- ANGLeD (NCT03613181)
- Testing
- ANG1005, Physician's Best Choice
- Volunteers
- 150 people
- Sponsor
- Angiochem Inc
Brain Metastasis, SRS
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
The goal of this clinical trial is to evaluate the efficacy of stereotactic radiotherapy in the treatment of brain metastases. The main question it aims to answer is: Did stereotactic radiotherapy improve LC rate in the treatment…
- Trial name
- NCT06852001
- Testing
- X-ray stereotactic radiotherapy for brain metastasis
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain Metastases
Perfexion Registration Using CBCT
Measuring precision radiation delivery through cone-beam computed tomography (CBCT) and intra-fraction motion management (IFMM) incorporated on a GammaKnife unit via the Leksell Coordinate Frame (LCF) and relocatable mask system…
- Trial name
- NCT04170777
- Where
- Canada
- Volunteers
- 1,250 people
- Sponsor
- University Health Network, Toronto
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis
This study intends to include HER2-positive metastatic breast cancer patients (with or without brain metastasis) who have become resistant to previous treatment with trastuzumab.
- Trial name
- NCT06015100
- Testing
- Inetetamab plus pyrotiniband and capecitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yan Xue
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.